A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression
Herbst R, Jassem J, Abogunrin S, James D, McCool R, Belleli R, Giaccone G, De Marinis F. A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression. Frontiers In Oncology 2021, 11: 676732. PMID: 34307144, PMCID: PMC8300186, DOI: 10.3389/fonc.2021.676732.Peer-Reviewed Original ResearchNon-small cell lung cancerProgression-free survivalObjective response rateStage IV non-small cell lung cancerFirst-line treatmentOverall survivalCell lung cancerLung cancerHigh Programmed-Death Ligand 1 (PD-L1) expressionMetastatic non-small cell lung cancerStage non-small cell lung cancerProgrammed Death Ligand 1 ExpressionTreatment-related adverse eventsDeath ligand 1 (PD-L1) expressionPD-L1 expressionPD-L1 statusAbsence of headNetwork Meta-AnalysisRisk of biasRandom-effects modelVersus ChemotherapyImmunotherapy regimenAdverse eventsHead trialsCombination regimens